
Christian Hinrichs
Chief, Cancer Immunotherapy · Rutgers Health
Credentials: · · · · ·
History
- Present
Cancer Immunotherapy Division · Rutgers Health
- Present
Center of Excellence in Cancer Immunology and Metabolism Leadership · Rutgers Health
- Present
Section of Cancer Immunotherapy · Rutgers Health
- 1996–1999
Internal Medicine
University of Missouri, Kansas
- 1992–1996
- 1988–1992
University of Missouri, Kansas
Research
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
Science · 2014 · 1,421 citations
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells
Nature Medicine · 2009 · 872 citations
Tumor-specific Th17-polarized cells eradicate large established melanoma
Blood · 2008 · 673 citations

23 papers · 6 as a fellow

15 papers · 2 as a fellow

10 papers
- CK
9 papers · 6 as a resident

8 papers

7 papers
- AB
5 papers
- SD
5 papers · 5 as a resident
Grants
- 2026–2031
Expanding the Reach of TCR-T Therapies for HPV16-Associated Cancers Beyond HLA-A*02:01
National Cancer Institute · R01
Contact PI · $651.5K · Rutgers Biomedical and Health Sciences
- 2024–2028
E7 TCR-T Cell Therapy for HPV-Associated Cancers
National Cancer Institute · U01
Contact PI · $1.9M · Rutgers Biomedical and Health Sciences
- 2023–2027
The Landscape of Tumor Intrinsic Genetic Resistance to T Cell Therapy
National Cancer Institute · R00
Contact PI · $2.4M · Rutgers Biomedical and Health Sciences
- 2024–2025
Developing TCR-T Cell Therapy in Renal Cell Carcinoma
National Cancer Institute · R21
PI · $403.7K · Rutgers Biomedical and Health Sciences
Clinical trials
- 2025–2026
Principal investigator · Recruiting · Phase 1, Phase 2
Christian Hinrichs
- 2023–2027
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
Principal investigator · Recruiting · Phase 2
Christian Hinrichs
- 2022–2030
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
Principal investigator · Recruiting · Phase 1
Christian Hinrichs
- 2020
Principal investigator · Withdrawn
National Cancer Institute (NCI)

